16 reports of this reaction
0.5% of all ACTIVATED CHARCOAL reports
#66 most reported adverse reaction
MUCOSAL INFLAMMATION is the #66 most commonly reported adverse reaction for ACTIVATED CHARCOAL, manufactured by Padagis US LLC. There are 16 FDA adverse event reports linking ACTIVATED CHARCOAL to MUCOSAL INFLAMMATION. This represents approximately 0.5% of all 3,053 adverse event reports for this drug.
ACTIVATED CHARCOAL has an overall safety score of 85 out of 100. Patients taking ACTIVATED CHARCOAL who experience mucosal inflammation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MUCOSAL INFLAMMATION is a less commonly reported adverse event for ACTIVATED CHARCOAL, but still significant enough to appear in the safety profile.
In addition to mucosal inflammation, the following adverse reactions have been reported for ACTIVATED CHARCOAL:
The following drugs have also been linked to mucosal inflammation in FDA adverse event reports:
MUCOSAL INFLAMMATION has been reported as an adverse event in 16 FDA reports for ACTIVATED CHARCOAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
MUCOSAL INFLAMMATION accounts for approximately 0.5% of all adverse event reports for ACTIVATED CHARCOAL, making it a notable side effect.
If you experience mucosal inflammation while taking ACTIVATED CHARCOAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.